Keyphrases
Acetylsalicylic Acid
11%
Acute Myocardial Infarction
32%
Advanced Therapies
27%
Advanced Therapy Medicinal Products
54%
Adverse Drug Reaction
100%
Adverse Reactions
12%
BNT162b2
26%
ChAdOx1
21%
Clinical Development
13%
Clinical Practice
42%
Clinical Trials
51%
Comorbidity
20%
Drug Provocation Test
14%
Drug Treatment
13%
Elderly Patients
16%
Elderly People
36%
Electronic Medical Records
13%
European Countries
19%
European Union
43%
Hip Fracture
14%
Hospital Setting
12%
Hydroxychloroquine
11%
Immunogenicity
13%
Inappropriate Prescribing
21%
Marketing Authorization
25%
Multicentric
12%
Multiple Sclerosis
12%
Off-label Use
43%
Older Patients
18%
Older People
12%
Pacientes
14%
Patient Register
12%
Pediatric Hematology
21%
Pharmacovigilance
29%
Pharmacovigilance System
16%
Polypharmacy
20%
Potentially Inappropriate Medication
21%
Reactogenicity
24%
Real-world Practice
12%
Regulatory Framework
12%
Rituximab
36%
SARS-CoV-2 Infection
12%
Secondary Prevention
21%
Spain
24%
Spontaneous Reporting
14%
STOPP Criteria
12%
Systemic Lupus Erythematosus
13%
Tertiary Hospital
20%
United States
32%
β-lactam Antibiotics
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
17%
Acute Heart Infarction
34%
Acute Kidney Failure
10%
Adrenergic Receptor Blocking Agent
10%
Adverse Drug Reaction
89%
Adverse Event
37%
Adverse Event
10%
Anticoagulant Agent
33%
Benzodiazepine
10%
Beta Adrenergic Receptor Blocking Agent
11%
Beta Lactam
11%
Beta Lactam Antibiotic
14%
Biological Product
10%
Clinical Pharmacology
10%
Clinical Trial
46%
Diabetes Mellitus
14%
Disease
35%
Diseases
10%
Ensure
10%
Ertapenem
10%
Heart Infarction
10%
Hip Fracture
21%
Hydroxychloroquine
11%
Immunoassay
14%
Immunogenicity
18%
Indicator
10%
Infection
18%
Infection
10%
Interferon
12%
Kidney Disease
11%
Messenger RNA
10%
Multiple Chronic Conditions
14%
Observational Study
16%
Off-Label Use
43%
Orphan Drug
10%
Pharmacoepidemiology
10%
Pharmacotherapy
14%
Pharmacovigilance
45%
Polypharmacy
18%
Prevalence
20%
Prospective Study
14%
Provocation Test
14%
Psychotropic Agent
10%
Receptor
21%
Remission
13%
Retrospective Study
43%
Rituximab
38%
SARS Coronavirus
28%
Systemic Lupus Erythematosus
11%
Vaccine
10%
Medicine and Dentistry
Acetylsalicylic Acid
10%
Acute Heart Infarction
10%
Acute Kidney Injury
10%
Advanced Therapy
43%
Adverse Drug Reaction
21%
Adverse Event
13%
Anticoagulation
10%
Antithrombotic
22%
Asthma
10%
Atrial Fibrillation
10%
Breathing
10%
Cardiovascular Risk
10%
Clinical Trial
25%
Coronary Angiography
10%
COVID-19 Vaccination
10%
Decision Making
10%
Diseases
15%
Drug Therapy
13%
Elderly Population
10%
Electronic Nose
10%
Health Care Cost
22%
Heart Muscle Revascularization
10%
Hip Fracture
10%
Hospital
10%
Human Immunoglobulin
10%
Hydroxychloroquine
10%
Immunoassay
12%
Immunogenicity
18%
Immunoglobulin
10%
Infection
13%
Malignant Neoplasm
14%
Medicine
13%
Messenger RNA
10%
Myositis
10%
Nephropathy
10%
Neutralization
13%
Observational Study
14%
Off-Label Use
10%
Orphan Drug
13%
Patient
16%
Programmed Death-Ligand 1
10%
Provocation Test
10%
Reactogenicity
25%
Receptor Binding
19%
Reimbursement
21%
Retrospective Study
22%
Rituximab
10%
Severe Acute Respiratory Syndrome Coronavirus 2
27%
Therapeutic Procedure
12%
β-Lactam antibiotic
10%